Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fa⦠read more
Healthcare
Biotechnology
21 years
USD
Exclusive to Premium users
$4.22
Price-0.47%
-$0.02
$269.976m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$36k
-
1y CAGR-
3y CAGR-
5y CAGR-$40.339m
-
1y CAGR-
3y CAGR-
5y CAGR-$0.64
-
1y CAGR-
3y CAGR-
5y CAGR-$117.167m
$15.602m
Assets$132.769m
Liabilities$120.510m
Debt772.4%
-3.6x
Debt to EBITDA-$35.620m
-
1y CAGR-
3y CAGR-
5y CAGR